Fluconazole Intravenous and Tracleer
Determining the interaction of Fluconazole Intravenous and Tracleer and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Fluconazole may increase the blood levels of bosentan. In some cases, this can increase the risk and/or severity of side effects such as nausea, vomiting, fatigue, headache, low blood pressure, fluid retention, anemia, and liver problems. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of bosentan, which is metabolized by these isoenzymes. When bosentan 125 mg orally twice a day was administered with the potent CYP450 3A4 inhibitor ketoconazole, bosentan plasma concentrations increased by approximately 2-fold. Concomitant administration of both a CYP450 2C9 inhibitor and a CYP450 3A4 inhibitor may lead to even larger increases in plasma concentrations of bosentan.
MANAGEMENT: The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered during coadministration with CYP450 2C9 or 3A4 inhibitors. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Concomitant administration of bosentan with both a potent CYP450 2C9 inhibitor (e.g., fluconazole, amiodarone) and a potent CYP450 3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir) is not recommended. Concomitant administration with dual inhibitors of CYP450 2C9 and 3A4 (e.g., delavirdine, imatinib, miconazole, voriconazole) should probably be avoided also, if possible.
- "Product Information. Tracleer (bosentan)." Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
Generic Name: fluconazole
Brand name: Diflucan
Synonyms: Fluconazole
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fluconazole Intravenous-Tracleer (Bosentan Tablets for Oral Suspension)
- Fluconazole Intravenous-Tracleer (Bosentan Tablets)
- Fluconazole Intravenous-Tradjenta
- Fluconazole Intravenous-Tramacet
- Fluconazole Intravenous-Tramadol
- Fluconazole Intravenous-Tramadol and acetaminophen
- Tracleer-Fluconazole Oral Suspension
- Tracleer-Fluconazole Tablets
- Tracleer-Flucytosine
- Tracleer-Fludara
- Tracleer-Fludara injection
- Tracleer-Fludarabine